Although our studies do not support a general turnaround of the melanocyte-to-NCC CpG-methylation profile during metastatic melanoma progression, they suggest metastatic progression depends on the reversal of NR2F2-Iso2 repression. The gene discussed is SLC12A3; the disease is metastatic melanoma.